Critical Path Management in Biomedical Startups: A Framework for Early Implementation

Today's investment environment requires biomedical companies to demonstrate not just scientific breakthroughs, but operational excellence from inception. The traditional approach of addressing regulatory pathways, quality systems, and clinical validation as sequential afterthoughts has become financially unsustainable. Instead, forward-thinking executives are integrating these elements into their foundational strategy, treating critical path management as a core competency rather than an administrative burden.

This shift reflects a broader transformation in our industry. As discussed in our previous article on biomedical data management:  proactive planning and systematic approaches are increasingly recognized as essential for competitive advantage.

Critical Path

Directors and investors are very aware of the critical path, which encompasses those activities that directly determine time-to-market and regulatory approval timelines. For diagnostic companies like Viva In Vitro, this typically includes 

• scientific and technical developments,
• design controls & quality management system
• manufacturing and design transfer planning
• regulatory roadmap execution
• reimbursement & market access preparation

Activities that are both time-sensitive and resource-intensive, making them particularly vulnerable to scope creep and inefficient execution.

Quality System Foundation

Implementing a quality management system aligned with ISO 13485 from the outset provides biomedical startups with the structural foundation for all subsequent critical path activities. This isn't merely about compliance—it's about 

• creating systematic processes that eliminate rework,
• structuring and preserving the knowhow the company creates,
• and about consistency throughout the whole development cycle.

Early quality system implementation also facilitates smoother interactions with regulatory bodies and potential partners. The investment in upfront systematization pays dividends through easier audit processes and faster time to market.

Clinical Evidence Strategy

Engage with customers, buyers, distributors, early on, as well as with regulatory bodies and find reliable, proven advisory and consulting firms in every field. Robust analytical and clinical studies designed to demonstrate efficacy, safety, sensitivity, specificity, precision, or reproducibility must be conceived with a view to access—and succeed—in specific market segments. This means moving beyond the minimum viable evidence approach to develop comprehensive validation frameworks that anticipate regulatory questions and market requirements.

Well thought out studies to be conducted early often eliminate the need for additional validation work later, when time pressures and resources are more constrained. These studies may also provide key insights into different use cases, benefiting your operational optimization.

Operational Optimization

In the case of Viva In Vitro, assay time optimization, protocol simplification, and efficient reagent utilization represent the operational focus, not only in the way we arrange our development, but also in how we design our product for efficient industrialization.

Said elements are not just sheer technical considerations, they are key elements that will favorably impact user adoption and market penetration. Companies that optimize these factors early may gain significant competitive advantage through reduced manufacturing costs, simplified training requirements, and enhanced user experience.

You will never regret having built this core competence in your organization; it will become particularly valuable when scaling operations or entering new geographic markets.

Implementation Imperatives

Executive commitment to treating these activities as investments rather than operational expenses involves 
hiring great professionals to build a team capable of “scaling up”, gradually pivoting from efficacy to increasing efficiency,
allocating senior management attention, 
and adequate resources to activities that create the foundation for sustainable growth.

Successful implementation also demands cross-functional coordination between scientific, regulatory, and market-access teams from the earliest stages of company development to prevent inefficiencies that compound over time.

Capital Efficiency

This team and customer-oriented framework enhances the company’s prospects of achieving crucial time savings–– largely due to reduced rework, smoother regulatory interactions, and streamlined validation processes, as explained.

Over the last years, efficient capital deployment has become a necessity for the survival of biomedical startups. The reality is that capital and government support are being diverted toward perceived geostrategic opportunities and emerging threats of our day, further extending our already prolonged fundraising cycles.  

Companies able to convey and execute an optimal approach on a well delimitated critical path to market, so as to prevent setbacks later on, will very likely achieve key milestones with significantly less capital than those that address these requirements reactively.

Looking Forward

It is a long race, and biomedicine is a field where decisions in early stage may have an unexpected inertia and cost. Be systematic in your critical path management from day one, or face compounding delays and capital inefficiencies that may prove terminal in today's demanding market environment. The companies that act early will not only survive—they will establish the operational foundations that enable sustained competitive advantage and long-term growth.

Co-authored by 
Pablo González Polanco
and Joaquín Gómez Moya